CMap Candidates
CMap (Connectivity Map) candidates are extracted from CLUE (CMap and LINCS Unified Environment), with detailed information, e.g., perturbagen time and dose, compound structure, targets, SMILES, mechanism of action. Two publicly available gene expression profiles of NAFLD are used to calculate individual connectivity scores and corresponding statistical significances for these candidates.
stats1
stats2
34330 records.
| CMap ID | Pert ID | Compound Name | Targets | MoA | Compound Aliases | |
|---|---|---|---|---|---|---|
| C04604 | BRD-K06974027 | BRD-K06974027 | -- | -- | -- | Details |
| C04605 | BRD-K06980535 | promazine | CHRM5; DRD2 | Dopamine receptor antagonist | -- | Details |
| C04606 | BRD-K06992369 | BRD-K06992369 | -- | -- | -- | Details |
| C04607 | BRD-K06994380 | BRD-K06994380 | -- | -- | -- | Details |
| C04608 | BRD-K06997715 | BRD-K06997715 | -- | -- | -- | Details |
| C04609 | BRD-K07001848 | BRD-K07001848 | -- | -- | -- | Details |
| C04610 | BRD-K07003080 | BRD-K07003080 | -- | -- | -- | Details |
| C04611 | BRD-K07004447 | BRD-K07004447 | -- | -- | -- | Details |
| C04612 | BRD-K07005393 | BRD-K07005393 | -- | -- | -- | Details |
| C04613 | BRD-K07008972 | BRD-K07008972 | -- | -- | -- | Details |
| C04614 | BRD-K07009788 | BRD-K07009788 | -- | -- | -- | Details |
| C04615 | BRD-K07011015 | BRD-K07011015 | -- | -- | 3-[(3-methylbenzyl)sulfanyl]-6-(2-thienyl)pyridazine | Details |
| C04616 | BRD-K07013504 | BRD-K07013504 | -- | -- | -- | Details |
| C04617 | BRD-K07017100 | BRD-K07017100 | -- | -- | -- | Details |
| C04618 | BRD-K07020302 | BRD-K07020302 | -- | -- | -- | Details |
| C04619 | BRD-K07020505 | BRD-K07020505 | -- | -- | -- | Details |
| C04620 | BRD-K07023879 | BRD-K07023879 | -- | -- | -- | Details |
| C04621 | BRD-K07025286 | BRD-K07025286 | -- | -- | -- | Details |
| C04622 | BRD-K07026322 | BRD-K07026322 | -- | -- | -- | Details |
| C04623 | BRD-K07029108 | BRD-K07029108 | -- | -- | -- | Details |
| C04624 | BRD-K07033348 | BRD-K07033348 | -- | -- | -- | Details |
| C04625 | BRD-K07035171 | BRD-K07035171 | -- | -- | -- | Details |
| C04626 | BRD-K07039703 | BRD-K07039703 | -- | -- | -- | Details |
| C04627 | BRD-K07040635 | BRD-K07040635 | -- | -- | -- | Details |
| C04628 | BRD-K07056593 | BRD-K07056593 | -- | -- | -- | Details |
| C04629 | BRD-K07060092 | BRD-K07060092 | -- | -- | -- | Details |
| C04630 | BRD-K07061353 | BRD-K07061353 | -- | -- | -- | Details |
| C04631 | BRD-K07063907 | BRD-K07063907 | -- | -- | -- | Details |
| C04632 | BRD-K07064094 | BRD-K07064094 | -- | -- | -- | Details |
| C04633 | BRD-K07070922 | PF-03049423 | -- | -- | -- | Details |
| C04634 | BRD-K07071690 | BRD-K07071690 | -- | -- | -- | Details |
| C04635 | BRD-K07073046 | BRD-K07073046 | -- | -- | -- | Details |
| C04636 | BRD-K07079548 | BRD-K07079548 | -- | -- | -- | Details |
| C04637 | BRD-K07080595 | hydrazobenzene | -- | -- | -- | Details |
| C04638 | BRD-K07081072 | BRD-K07081072 | -- | -- | -- | Details |
| C04639 | BRD-K07100440 | BRD-K07100440 | -- | -- | -- | Details |
| C04640 | BRD-K07101857 | BRD-K07101857 | -- | -- | -- | Details |
| C04641 | BRD-K07103434 | pyrvinium-pamoate | AR | Akt inhibitor; Androgen receptor antagonist | -- | Details |
| C04642 | BRD-K07104840 | SA-1455938 | -- | -- | -- | Details |
| C04643 | BRD-K07105437 | BRD-K07105437 | -- | -- | -- | Details |
| C04644 | BRD-K07106112 | BMS-599626 | EGFR; ERBB2; ERBB4 | EGFR inhibitor; Receptor tyrosine protein kinase inhibitor | -- | Details |
| C04645 | BRD-K07107626 | BRD-K07107626 | -- | -- | -- | Details |
| C04646 | BRD-K07110772 | SA-433965 | -- | -- | -- | Details |
| C04647 | BRD-K07117950 | imperatorin | -- | -- | -- | Details |
| C04648 | BRD-K07125273 | SA-1473468 | -- | -- | -- | Details |
| C04649 | BRD-K07129792 | BRD-K07129792 | -- | -- | -- | Details |
| C04650 | BRD-K07142677 | BRD-K07142677 | -- | -- | -- | Details |
| C04651 | BRD-K07152092 | BRD-K07152092 | -- | -- | -- | Details |
| C04652 | BRD-K07157902 | BRD-K07157902 | -- | -- | -- | Details |
| C04653 | BRD-K07160047 | fiacitabine | -- | -- | -- | Details |
| C04654 | BRD-K07160568 | BRD-K07160568 | -- | -- | -- | Details |
| C04655 | BRD-K07160586 | BRD-K07160586 | -- | -- | [(4-oxo-2-phenyl-4H-chromen-3-yl)oxy]acetic acid | Details |
| C04656 | BRD-K07161233 | BRD-K07161233 | -- | -- | -- | Details |
| C04657 | BRD-K07164057 | BRD-K07164057 | -- | -- | -- | Details |
| C04658 | BRD-K07164317 | BRD-K07164317 | -- | -- | -- | Details |
| C04659 | BRD-K07184814 | BRD-K07184814 | -- | -- | -- | Details |
| C04660 | BRD-K07188707 | BRD-K07188707 | -- | -- | -- | Details |
| C04661 | BRD-K07196884 | BRD-K07196884 | -- | -- | -- | Details |
| C04662 | BRD-K07197565 | BRD-K07197565 | -- | -- | -- | Details |
| C04663 | BRD-K07208025 | trimethoprim | -- | -- | -- | Details |
| C04664 | BRD-K07208716 | BRD-K07208716 | -- | -- | -- | Details |
| C04665 | BRD-K07212038 | selinidin | -- | -- | -- | Details |
| C04666 | BRD-K07220430 | cinnarizine | HRH1 | Calcium channel blocker | -- | Details |
| C04667 | BRD-K07223205 | BRD-K07223205 | -- | -- | -- | Details |
| C04668 | BRD-K07230804 | BRD-K07230804 | -- | -- | -- | Details |
| C04669 | BRD-K07237224 | moclobemide | MAOA | Monoamine oxidase inhibitor | -- | Details |
| C04670 | BRD-K07237640 | BRD-K07237640 | -- | -- | -- | Details |
| C04671 | BRD-K07244661 | BRD-K07244661 | -- | -- | -- | Details |
| C04672 | BRD-K07245666 | BRD-K07245666 | -- | -- | -- | Details |
| C04673 | BRD-K07250107 | BRD-K07250107 | -- | -- | -- | Details |
| C04674 | BRD-K07253943 | BRD-K07253943 | -- | -- | -- | Details |
| C04675 | BRD-K07257078 | BRD-K07257078 | -- | -- | -- | Details |
| C04676 | BRD-K07259155 | BRD-K07259155 | -- | -- | -- | Details |
| C04677 | BRD-K07265709 | razoxane | -- | -- | dexrazoxane | Details |
| C04678 | BRD-K07269289 | BRD-K07269289 | -- | -- | -- | Details |
| C04679 | BRD-K07270511 | BRD-K07270511 | -- | -- | -- | Details |
| C04680 | BRD-K07274638 | BRD-K07274638 | -- | -- | -- | Details |
| C04681 | BRD-K07275374 | BRD-K07275374 | -- | -- | -- | Details |
| C04682 | BRD-K07275921 | BRD-K07275921 | -- | -- | -- | Details |
| C04683 | BRD-K07276022 | BRD-K07276022 | -- | -- | -- | Details |
| C04684 | BRD-K07276035 | BRD-K07276035 | -- | -- | -- | Details |
| C04685 | BRD-K07276273 | BRD-K07276273 | -- | -- | -- | Details |
| C04686 | BRD-K07278381 | BRD-K07278381 | -- | -- | -- | Details |
| C04687 | BRD-K07278815 | BRD-K07278815 | -- | -- | -- | Details |
| C04688 | BRD-K07281036 | BRD-K07281036 | -- | -- | -- | Details |
| C04689 | BRD-K07291429 | BRD-K07291429 | -- | -- | -- | Details |
| C04690 | BRD-K07298353 | BRD-K07298353 | -- | -- | -- | Details |
| C04691 | BRD-K07298554 | BRD-K07298554 | -- | -- | -- | Details |
| C04692 | BRD-K07300437 | BRD-K07300437 | -- | -- | -- | Details |
| C04693 | BRD-K07303502 | BRD-K07303502 | -- | -- | arachidonyl-trifluoro-methane | Details |
| C04694 | BRD-K07303702 | BRD-K07303702 | -- | -- | -- | Details |
| C04695 | BRD-K07307589 | BRD-K07307589 | -- | -- | -- | Details |
| C04696 | BRD-K07310275 | PF-04691502 | MTOR; PIK3CA | MTOR inhibitor; PI3K inhibitor | -- | Details |
| C04697 | BRD-K07313741 | BRD-K07313741 | -- | -- | -- | Details |
| C04698 | BRD-K07315344 | BRD-K07315344 | -- | -- | -- | Details |
| C04699 | BRD-K07323881 | BRD-K07323881 | -- | -- | -- | Details |
| C04700 | BRD-K07325606 | hispidin | PRKCB | PKC inhibitor | -- | Details |
| C04701 | BRD-K07327532 | BRD-K07327532 | -- | -- | -- | Details |
| C04702 | BRD-K07329815 | BRD-K07329815 | -- | -- | -- | Details |
| C04703 | BRD-K07336866 | BRD-K07336866 | -- | -- | -- | Details |